A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

August 5, 2026 updated by: Eli Lilly and Company

A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
400

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

  • Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • Phone Number: 317-615-4559
  • Email: LillyTrials@Lilly.com

Study Locations

  • United States
    • Arizona
      • Chandler, Arizona, United States, 85225
        • Recruiting
        • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
        • Principal Investigator:
          • Yessica Sachdeva
      • Scottsdale, Arizona, United States, 85260
        • Recruiting
        • Headlands Research - Scottsdale
        • Principal Investigator:
          • Benjamin Clark
      • Tucson, Arizona, United States, 85712
        • Recruiting
        • The Institute for Liver Health II dba Arizona Liver Health-Tucson
        • Principal Investigator:
          • Anita Kohli
    • California
      • Greenbrae, California, United States, 94904
        • Recruiting
        • NorCal Medical Research, Inc
        • Principal Investigator:
          • Linda Gaudiani
      • Huntington Park, California, United States, 90255
        • Recruiting
        • Velocity Clinical Research, Huntington Park
        • Principal Investigator:
          • Stanley Hsia
      • Rolling Hills Estates, California, United States, 90274
        • Recruiting
        • Peninsula Research Associates
        • Principal Investigator:
          • LeighAnn Schmidt
      • Walnut Creek, California, United States, 94598
        • Recruiting
        • Diablo Clinical Research, Inc.
        • Principal Investigator:
          • Mark Christiansen
    • Connecticut
      • Stamford, Connecticut, United States, 06905
        • Recruiting
        • Stamford Therapeutics Consortium
        • Principal Investigator:
          • David Radin
    • Florida
      • Miami, Florida, United States, 33165
        • Recruiting
        • New Horizon Research Center
        • Principal Investigator:
          • Lazaro Nunez
      • Miami Lakes, Florida, United States, 33016
        • Recruiting
        • Indago Research & Health Center, Inc
        • Principal Investigator:
          • Jose Cardona
      • New Port Richey, Florida, United States, 34652
        • Recruiting
        • Suncoast Clinical Research, Inc.
        • Principal Investigator:
          • Cathy Barnes
      • Orlando, Florida, United States, 32803
        • Recruiting
        • Charter Research - Winter Park
        • Principal Investigator:
          • Edgardo Rivera-Rivera
      • The Villages, Florida, United States, 32162
        • Recruiting
        • Charter Research - Lady Lake
        • Principal Investigator:
          • Jeffrey Norton
    • Idaho
      • Ammon, Idaho, United States, 83406
        • Recruiting
        • Medical Research Partners
        • Principal Investigator:
          • Joseph Moore
    • Illinois
      • Chicago, Illinois, United States, 60640
        • Recruiting
        • Great Lakes Clinical Trials - Ravenswood
        • Principal Investigator:
          • Rupal Trivedi
    • Kansas
      • Topeka, Kansas, United States, 66606
        • Recruiting
        • Cotton O'Neil Diabetes & Endocrinology
        • Principal Investigator:
          • susan brian
    • Kentucky
      • Louisville, Kentucky, United States, 40213
        • Recruiting
        • Monroe Biomedical Research - Louisville
        • Principal Investigator:
          • Harold Bays
    • Massachusetts
      • Needham, Massachusetts, United States, 02492
        • Recruiting
        • Knownwell
        • Principal Investigator:
          • Angela Fitch
      • New Bedford, Massachusetts, United States, 02740
        • Recruiting
        • Lucida Clinical Trials
        • Principal Investigator:
          • David Shih
    • Michigan
      • Southfield, Michigan, United States, 48034
        • Recruiting
        • Headlands Research - Detroit
        • Principal Investigator:
          • Christopher Romero
      • Troy, Michigan, United States, 48098
        • Recruiting
        • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
        • Principal Investigator:
          • Neil Fraser
    • Missouri
      • City of Saint Peters, Missouri, United States, 63303
        • Recruiting
        • StudyMetrix Research
        • Principal Investigator:
          • Timothy Smith
      • Springfield, Missouri, United States, 65807
        • Recruiting
        • Clinvest Headlands Llc
        • Principal Investigator:
          • Christina Capps
    • Nevada
      • Las Vegas, Nevada, United States, 89128
        • Recruiting
        • Las Vegas Medical Research
        • Principal Investigator:
          • Cornell Calinescu
    • New York
      • Amherst, New York, United States, 14226
        • Recruiting
        • Dent Neurologic Institute
        • Principal Investigator:
          • Laszlo Mechtler
      • Rochester, New York, United States, 14609
        • Recruiting
        • Rochester Clinical Research, LLC
        • Principal Investigator:
          • Patrick Connors
    • North Carolina
      • Greensboro, North Carolina, United States, 27405
        • Recruiting
        • Medication Management
        • Principal Investigator:
          • James Franklin
      • Monroe, North Carolina, United States, 28112
        • Recruiting
        • Monroe Biomedical Research
        • Principal Investigator:
          • Awawu Igbinadolor
      • Morehead City, North Carolina, United States, 28557
        • Recruiting
        • Lucas Research, Inc
        • Principal Investigator:
          • Kathryn Lucas
      • New Bern, North Carolina, United States, 28562
        • Recruiting
        • Lucas Research, Inc.
        • Principal Investigator:
          • Joseph Maides
    • Ohio
      • Cincinnati, Ohio, United States, 45212
        • Recruiting
        • CTI Clinical Research Center
        • Principal Investigator:
          • James Maynard
    • South Carolina
      • Greenville, South Carolina, United States, 29607
        • Recruiting
        • Tribe Clinical Research, LLC
        • Principal Investigator:
          • Ronald Mayfield
    • Tennessee
      • Nashville, Tennessee, United States, 37211
        • Recruiting
        • Quality Medical Research
        • Principal Investigator:
          • Saras Sharma
    • Texas
      • Austin, Texas, United States, 78745
        • Recruiting
        • IMA Clinical Research Austin
        • Principal Investigator:
          • Nomita Kim
      • Dallas, Texas, United States, 75251
        • Recruiting
        • FutureSearch Trials of Dallas
        • Principal Investigator:
          • Michael Downing
      • Houston, Texas, United States, 77079
        • Recruiting
        • PlanIt Research, PLLC
        • Principal Investigator:
          • Amer Al-Karadsheh
      • San Antonio, Texas, United States, 78240
        • Recruiting
        • Endeavor Clinical Trials
        • Principal Investigator:
          • Nitendra Agarwal
      • Weslaco, Texas, United States, 78596
        • Recruiting
        • Texas Valley Clinical Research
        • Principal Investigator:
          • Eduardo Luna
    • Virginia
      • Danville, Virginia, United States, 24541
        • Recruiting
        • Sovah Clinical Research-River District
        • Principal Investigator:
          • Stephan Jannach
    • Washington
      • Wenatchee, Washington, United States, 98801
        • Recruiting
        • Central Washington Health Services Association d/b/a Confluence Health
        • Principal Investigator:
          • Kathryn Eren

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • See Master Protocol CWMM (NCT06143956) for inclusion criteria

Exclusion Criteria:

In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):

  • Have type 1 diabetes or type 2 diabetes
  • Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
  • Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
  • Have a history of acute or chronic pancreatitis
  • All concomitant medications should be at a stable dose for at least 3 months prior to screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Placebo
Participants will receive placebo SC
Drug: Placebo
Administered SC
Experimental: Eloralintide Dose 2
Participants will receive eloralintide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Experimental: Eloralintide Dose 3
Participants will receive eloralintide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Experimental: Macupatide Dose 1
Participants will receive macupatide subcutaneously (SC)
Drug: Macupatide
Administered SC
Other Names:
  • LY3532226
Experimental: Eloralintide Dose 1
Participants will receive eloralintide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Experimental: Macupatide Dose 1 + Eloralintide Dose 1
Participants will receive macupatide SC and eloralintide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Drug: Macupatide
Administered SC
Other Names:
  • LY3532226
Experimental: Macupatide Dose 1 + Eloralintide Dose 2
Participants will receive macupatide SC and eloralintide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Drug: Macupatide
Administered SC
Other Names:
  • LY3532226
Experimental: Macupatide Dose 2 + Eloralintide Dose 3
Participants will receive macupatide SC and eloralintide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Drug: Macupatide
Administered SC
Other Names:
  • LY3532226

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Percent Change from Baseline in Body Weight
Time Frame: Baseline, Week 36
Baseline, Week 36

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Percent Change from Baseline in Body Weight
Time Frame: Baseline, Week 48
Baseline, Week 48
Change from Baseline in Body Mass Index (BMI)
Time Frame: Baseline, Week 36
Baseline, Week 36
Change from Baseline in Body Weight
Time Frame: Baseline, Week 36
Baseline, Week 36
Percentage of Participants who Achieve ≥5% Body Weight Reduction
Time Frame: Week 36
Week 36
Percentage of Participants who Achieve ≥10% Body Weight Reduction
Time Frame: Week 36
Week 36

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Eli Lilly and Company

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 15, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 1, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 11, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 11, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 15, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 6, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 5, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 27844
  • W8M-MC-CWMM (Other Identifier: Eli Lilly and Company)
  • W8M-MC-MC01 (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD Sharing Time Frame

Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

IPD Sharing Access Criteria

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings